医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Alvogen Launches First Generic Equivalent of CopaxoneTM in Europe

2016年09月05日 PM09:43
このエントリーをはてなブックマークに追加


 

PINE BROOK, N.J.

Alvogen today announced the launch of RemurelTM (glatiramer acetate), the first generic equivalent of CopaxoneTM in Central and Eastern Europe. The product will be marketed as a once daily subcutaneous 20 mg prefilled syringe under the brand name RemurelTM and will be launched throughout all Central and Eastern European countries from September 2016 onwards.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160905005349/en/

Remurel (glatiramer acetate), the first generic equivalent of Copaxone (Photo: Business Wire)

Remurel (glatiramer acetate), the first generic equivalent of Copaxone (Photo: Business Wire)

The product will be launched with a proprietary auto-injector device (AutoxonTM) having multiple features to help support MS patients in their treatment with RemurelTM. Teva‘s CopaxoneTM delivered sales of over EUR 510 million in Europe in 2015, according to IMS Midas data.

Hacho Hatchikian, Executive Vice President at Alvogen in the CEE region, commented: “We are proud to announce the launch of RemurelTM. This product represents an important milestone in our growing portfolio in the region. It is also a landmark for Alvogen and MS patients throughout the CEE region, who will finally have access to an affordable high quality treatment for this chronic and neurodegenerative disease. This is yet another first-to-market complex product in our portfolio, testifying to Alvogen’s commitment in delivering difficult-to-make but affordable treatments to patients. RemurelTM offers a more affordable – but equally effective – treatment option for Multiple Sclerosis patients, offering compelling cost saving opportunities within the Central and Eastern European region.”

RemurelTM is indicated for the treatment of patients with relapsing-forms of multiple sclerosis (RRMS), a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. RemurelTM 20 mg was determined by the European health authorities to be therapeutically equivalent to daily CopaxoneTM 20 mg, with the same active ingredients, route of administration, strength and dosage form. This approval was supported by a large-scale, multicenter Phase III study, known as GATE (Glatiramer Acetate clinical Trial to assess Equivalence to Copaxone®). Results of the study demonstrate equivalence in efficacy and safety and support the safety of switching active therapy from CopaxoneTM to RemurelTM.

About Alvogen

Alvogen is a global, privately owned pharmaceutical company focused on developing, manufacturing and selling generic, brand, over-the-counter brands (OTC) and biosimilar products for patients around the world. The company has commercial operations in 35 countries with 2,300 employees and operates four manufacturing and development hubs in the US, Romania, Korea and Taiwan. North America is Alvogen’s single largest market and other key markets include: South Korea, Romania, Bulgaria, Hungary, Russia, Poland, Taiwan, Thailand, Ukraine, West Balkan, Japan and China.

CopaxoneTM is a registered trademark of Teva Pharmaceuticals Industry Ltd.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160905005349/en/

CONTACT

Alvogen
Halldor Kristmannsson
Vice President Global Marketing
& Communication
halldor.kristmannsson@alvogen.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease